13 Nov 2013, BioSpectrum Bureau , BioSpectrum
Singapore: WuXi PharmaTech, a China-based contract research organization (CRO), has obtained a multiyear license to Admet Predictor from Simulations Plus, a prediction software company.
Simulations Plus is a developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide.
Mr John DiBella, vice president of marketing and sales, Simulations Plus, said that, “We’re very pleased that WuXi has elected to license the Admet Predictor Toxicity Module. WuXi offers a variety of in vitro and in vivo services to assist its customers in pharmaceutical research and development. The Admet Predictor Toxicity Module provides more than 30 different kinds of toxicity predictions, requiring only molecular structures as input."
He further said, "These in silico predictions will provide WuXi with an additional service offering and are expected to assist both in prioritizing which in vitro assays need to be run for particular drugs and by filling in the gaps in in vitro data in support of pre-IND (initial new drug) and IND filings with regulatory agencies for WuXi’s customers. This license is the result of the combined efforts of Simulations Plus and PharmoGo, our distributor in China.”